Who
Leonard M. Greenstein
CFO, Treasurer
Company insider
Files Form 4 as: CFO, Treasurer, Carlsmed; Chief Financial Officer, Tarsus Pharmaceuticals; VP Finance & Corp Controller, Endologix Inc /de/.
In numbers
- Trades disclosed
- 35
- Buys
- 0
- Sells
- 15
- Bought
- $0
- Sold
- $726K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 2 May 2011
- Last trade
- 28 Jan 2026
- Last filed
- 30 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 Jan 2026filed 30 Jan 2026 | CARL CarlsmedMedical Devices | SEC FORM 4 Code A | —44,977 at $0.00 | filing |
| 28 Jan 2026filed 30 Jan 2026 | CARL CarlsmedMedical Devices | SEC FORM 4 Code A | —44,977 at $0.00 | filing |
| 22 Jul 2025filed 24 Jul 2025 | CARL Carlsmedoption or derivative · Medical Devices | SEC FORM 4 Code A | —71,429 at $0.00 | filing |
| 20 Apr 2023filed 21 Apr 2023 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $70K5,000 at $14.02 | filing |
| 23 Mar 2023filed 23 Mar 2023 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $4,204346 at $12.15 | filing |
| 22 Mar 2023filed 23 Mar 2023 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $4,196332 at $12.64 | filing |
| 21 Mar 2023filed 23 Mar 2023 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $4,202326 at $12.89 | filing |
| 20 Mar 2023filed 21 Mar 2023 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $4,199333 at $12.61 | filing |
| 17 Mar 2023filed 21 Mar 2023 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $4,196316 at $13.28 | filing |
| 16 Mar 2023filed 17 Mar 2023 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $4,204313 at $13.43 | filing |
| 16 Mar 2023filed 17 Mar 2023 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $67K5,000 at $13.44 | filing |
| 15 Mar 2023filed 17 Mar 2023 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,462 at $0.00 | filing |
| 15 Mar 2023filed 17 Mar 2023 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —4,462 | filing |
| 8 Mar 2023filed 10 Mar 2023 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,097 at $0.00 | filing |
| 8 Mar 2023filed 10 Mar 2023 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,160 at $0.00 | filing |
| 16 Feb 2023filed 17 Feb 2023 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $76K5,000 at $15.12 | filing |
| 19 Jan 2023filed 20 Jan 2023 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $73K5,000 at $14.56 | filing |
| 15 Dec 2022filed 16 Dec 2022 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $73K5,000 at $14.64 | filing |
| 17 Nov 2022filed 18 Nov 2022 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $83K5,000 at $16.54 | filing |
| 20 Oct 2022filed 28 Oct 2022 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $78K4,877 at $15.90 | filing |
News
Reviewing Tarsus Pharmaceuticals (NASDAQ:TARS) and Novo Nordisk A/S (NYSE:NVO)TARS · themarketsdaily.com · 10 Oct 2026
0 headlines in the last 90 days name Leonard M. Greenstein; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.